文献速递衰弱、肌少症与跌倒多重用药

澳大利亚、中国、日本和西班牙养老院衰弱居民的处方精简机会:多中心研究

Deprescribing Opportunities for Frail Residents of Nursing Homes: A Multicenter Study in Australia, China, Japan, and Spain.
PubMed 文献 · J Am Med Dir Assoc · 2024-02-26

该研究基于4个队列研究数据,纳入31家养老院的1142名居民,比较澳大利亚、中国、日本和西班牙养老院中STOPPFrail药物按衰弱状态的患病率。结果显示非衰弱、衰弱和最衰弱居民中分别有84.7%、95.6%和90.6%使用至少一种STOPPFrail药物,不同药物在各队列间存在总体和衰弱特异性差异。

要点

  • 衰弱居民中STOPPFrail药物使用普遍,衰弱者95.6%使用至少一种。
  • 抗高血压药、维生素D、降脂药、阿司匹林、PPI和降糖药使用率国家间差异显著。
  • 部分药物随衰弱加重使用率变化趋势国家间不一致,反映处方文化差异。

核心结论

  • 不同队列间STOPPFrail药物总体和衰弱特异性患病率存在差异,可能反映处方文化、指南应用及医患态度不同。

研究设计与样本

  • 对4个队列研究数据进行二次横断面分析,纳入31家养老院共1142名居民,用药数据取自居民记录,衰弱采用FRAIL-NH量表评估(非衰弱0-2分,衰弱3-6分,最衰弱7-14分)。

主要发现

  • 非衰弱、衰弱和最衰弱居民中分别有84.7%、95.6%和90.6%使用至少一种STOPPFrail药物。
  • 最普遍STOPPFrail药物包括抗高血压药(中国53.0%至澳大利亚73.3%,P < .001)、维生素D(中国为零至澳大利亚52.7%,P < .001)、降脂治疗(日本11.1%至澳大利亚38.9%,P < .001)、阿司匹林(日本13.5%至中国26.2%,P < .001)、质子泵抑制剂(日本2.1%至澳大利亚32.0%,P < .001)和降糖药(日本12.3%至中国23.5%,P = .010)。
  • 与非最衰弱居民相比,非衰弱和衰弱居民中抗高血压药(PR,1.15;95% CI,1.06-1.25)、降脂治疗(PR,1.78;95% CI,1.45-2.18)、阿司匹林(PR,1.31;95% CI,1.04-1.64)和降糖药(PR,1.31;95% CI,1.00-1.72)使用更普遍。
  • 在中国和日本,抗高血压药使用随衰弱加重而更普遍,但在澳大利亚则随衰弱加重而较少普遍;降糖药使用在中国和西班牙随衰弱加重而较少普遍,在澳大利亚和日本各衰弱组间一致。

关键数值与推荐

  • STOPPFrail药物包括抗高血压药、维生素D、降脂治疗、阿司匹林、质子泵抑制剂和降糖药,其使用率按FRAIL-NH衰弱分组比较。

临床怎么用

  • 老年医学科医生应关注养老院衰弱居民的STOPPFrail药物使用,结合衰弱状态评估处方精简机会,但需考虑国家处方文化差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Deprescribing opportunities may differ across health care systems, nursing home settings, and prescribing cultures. The objective of this study was to compare the prevalence of STOPPFrail medications according to frailty status among residents of nursing homes in Australia, China, Japan, and Spain. DESIGN: Secondary cross-sectional analyses of data from 4 cohort studies. SETTING AND PARTICIPANTS: A total of 1142 residents in 31 nursing homes. METHODS: Medication data were extracted from resident records. Frailty was assessed using the FRAIL-NH scale (non-frail 0-2; frail 3-6; most-frail 7-14). Chi-square tests and prevalence ratios (PRs) were used to compare STOPPFrail medication use across cohorts. RESULTS: In total, 84.7% of non-frail, 95.6% of frail, and 90.6% of most-frail residents received ≥1 STOPPFrail medication. Overall, the most prevalent STOPPFrail medications were antihypertensives (53.0% in China to 73.3% in Australia, P < .001), vitamin D (nil in China to 52.7% in Australia, P < .001), lipid-lowering therapies (11.1% in Japan to 38.9% in Australia, P < .001), aspirin (13.5% in Japan to 26.2% in China, P < .001), proton pump inhibitors (2.1% in Japan to 32.0% in Australia, P < .001), and antidiabetic medications (12.3% in Japan to 23.5% in China, P = .010). Overall use of antihypertensives (PR, 1.15; 95% CI, 1.06-1.25), lipid-lowering therapies (PR, 1.78; 95% CI, 1.45-2.18), aspirin (PR, 1.31; 95% CI, 1.04-1.64), and antidiabetic medications (PR, 1.31; 95% CI, 1.00-1.72) were more prevalent among non-frail and frail residents compared with most-frail residents. Antihypertensive use was more prevalent with increasing frailty in China and Japan, but less prevalent with increasing frailty in Australia. Antidiabetic medication use was less prevalent with increasing frailty in China and Spain but was consistent across frailty groups in Australia and Japan. CONCLUSIONS AND IMPLICATIONS: There were overall and frailty-specific variations in prevalence of different STOPPFrail medications across cohorts. This may reflect differences in prescribing cultures, application of clinical practice guidelines in the nursing home setting, and clinician or resident attitudes toward deprescribing.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Liau SJ, Zhao M, Hamada S, et al. Deprescribing Opportunities for Frail Residents of Nursing Homes: A Multicenter Study in Australia, China, Japan, and Spain. J Am Med Dir Assoc. 2024. PMID: 38423513. doi:10.1016/j.jamda.2024.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。